HomeCompareERMAF vs JNJ

ERMAF vs JNJ: Dividend Comparison 2026

ERMAF yields 3.07% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ERMAF wins by $465.96M in total portfolio value
10 years
ERMAF
ERMAF
● Live price
3.07%
Share price
$55.45
Annual div
$1.70
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$465.99M
Annual income
$438,556,571.04
Full ERMAF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — ERMAF vs JNJ

📍 ERMAF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodERMAFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ERMAF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ERMAF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ERMAF
Annual income on $10K today (after 15% tax)
$261.06/yr
After 10yr DRIP, annual income (after tax)
$372,773,085.38/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, ERMAF beats the other by $372,769,099.39/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ERMAF + JNJ for your $10,000?

ERMAF: 50%JNJ: 50%
100% JNJ50/50100% ERMAF
Portfolio after 10yr
$233.01M
Annual income
$219,280,630.22/yr
Blended yield
94.11%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

ERMAF
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
1.2
Piotroski
2/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ERMAF buys
0
JNJ buys
0
No recent congressional trades found for ERMAF or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricERMAFJNJ
Forward yield3.07%2.13%
Annual dividend / share$1.70$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%28%
Portfolio after 10y$465.99M$30.3K
Annual income after 10y$438,556,571.04$4,689.40
Total dividends collected$463.96M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: ERMAF vs JNJ ($10,000, DRIP)

YearERMAF PortfolioERMAF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$11,314$614.25$10,592$272.30+$722.00ERMAF
2$13,405$1,299.02$11,289$357.73+$2.1KERMAF
3$17,220$2,876.81$12,123$472.89+$5.1KERMAF
4$25,333$6,907.58$13,141$629.86+$12.2KERMAF
5$46,101$18,994.26$14,408$846.81+$31.7KERMAF
6$113,936$64,607.80$16,021$1,151.60+$97.9KERMAF
7$420,368$298,456.51$18,122$1,588.22+$402.2KERMAF
8$2,508,035$2,058,240.95$20,930$2,228.20+$2.49MERMAF
9$25,636,962$22,953,365.39$24,792$3,191.91+$25.61MERMAF
10$465,988,121$438,556,571.04$30,274$4,689.40+$465.96MERMAF

ERMAF vs JNJ: Complete Analysis 2026

ERMAFStock

ERAMET S.A. operates as a mining and metallurgical company worldwide. The company extracts and processes manganese ore, nickel ore, and mineral sands. It also produces ferronickel, high purity nickel metal, nickel salts, nickel and cobalt chlorides, nickel carbonate, nickel ferroalloys, and other metallic salts used in stainless steel, catalysis and pigments, and alloy steel and casting; manganese alloys, such as high-carbon ferromanganese, silicomanganese, low and medium-carbon ferromanganese, and low-carbon silicomanganese for use in batteries, fertilizers, pigments, different reagents, construction, and automotive industries; and mineral sands, such as titanium dioxide, high-purity pig iron, zircon, and ilmenite used in ceramics and pigments. In addition, it operates Moanda mine in Gabon; nickel mines in New Caledonia and Indonesia; and mineral sand mine in Senegal and Argentina. ERAMET S.A. was incorporated in 1880 and is headquartered in Paris, France.

Full ERMAF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this ERMAF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ERMAF vs SCHDERMAF vs JEPIERMAF vs OERMAF vs KOERMAF vs MAINERMAF vs ABBVERMAF vs MRKERMAF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.